Curis is developing targeted small molecule drug candidates for cancer indications where there are substantial unmet therapeutic needs.

The Hedgehog pathway inhibitor Erivedge™ (vismodegib) is our most advanced molecule and is being commercialized and developed in collaboration with Genentech (Roche), a member of the Roche Group.  Genentech and Roche are responsible for the clinical development and commercialization of Erivedge.  Erivedge is currently marketed and sold in the U.S., approved for use in Israel and Mexico and is under regulatory review seeking commercialization in Europe, Australia and other territories.  Erivedge is also the subject of an ongoing Phase II clinical trial in patients with less severe forms of basal cell carcinoma.  There are several additional Phase I and II clinical trials ongoing under a collaboration between Genentech and independent investigators and the National Cancer Institute.

Our second development candidate under collaboration is Debio 0932, an HSP90 inhibitor that Curis licensed to Debiopharm Group in August 2009 and is currently the subject of a Phase I/II trial in advanced non-small cell lung cancer and has recently completed Phase Ib clinical testing in solid tumors, including in non-small cell lung cancer patients.  Debiopharm also plans to initiate an additional clinical trial during the second half of 2013 to test Debio 0932 in advanced renal cell carcinoma patients.

Curis has focused most of its internal resources on developing additional small molecule targeted cancer drug candidates. Curis is currently developing several proprietary clinical-stage small molecules in testing for various cancers, including antagonist of IAP proteins CUDC-427, dual PI3K and HDAC inhibitor CUDC-907 and EGFR/Her2 and HDAC inhibitor CUDC-101. 

Because of the early stages of development of most these programs, Curis' ability and that of the Company's collaborators and licensors to successfully complete preclinical and clinical studies of these product candidates, and the timing of completion of such programs, is highly uncertain.